PXL01 program entering Phase III clinical trial

A biotech with global reach

Therapeutic peptides for bioactive wound care

Two first-in-category product candidates

New medical concept with extraordinary safety

Strategic partnerships in EU, Asia and USA

Innovative treatments for local administration

Press releases

February 20, 2019Invitation to Presentation of Promore Pharma’s Year-end report for 2018
February 1, 2019Promore Pharma modifies its Phase III trial of PXL01 and expands the number of clinics in the study
January 31, 2019Subscription price for Promore Pharma’s warrants TO1 determined
December 17, 2018PharmaResearch Products Ltd use call option in Promore Pharma

More Press Releases

Interim report January – September 2018

Promore Pharma AB (publ) published its interim report for the third quarter 2018 on November 23, 2018.

Read the report

Calendar

February 26, 2019Year-end report 2018
February 26, 2019Invitation to Presentation of Promore Pharma’s Year-end report for 2018
March 12, 2019Redeye AWC (Advanced Wound Care) Seminar

More Events

Promore Pharma is a biopharmaceutical company specialized in the development of therapeutic peptides for the bioactive wound care market. The company’s aim is to develop two first-in-category products for indications with very few efficacious prescription pharmaceuticals, addressing high unmet medical need.

Vision

The vision of Promore Pharma is to solve the global medical problems of scarring, adhesions and chronic wounds.

Market

Within the global wound care market Promore Pharma’s product candidates are intended for the bioactive wound care segment. The bioactive wound care segment constitutes the fastest growing segment within the overall wound care market with a projected annual growth rate from 2015-2020 of 14 percent and is expected to reach USD 7.3 billion in 2020.